Citi lowered the firm’s price target on Harpoon Therapeutics (HARP) to $33 from $60 and keeps a Buy rating on the shares. The firm reduced its PN217 probability of success assumption to 15% from 20% after AbbVie (ABBV) declined its option. Citi also removed future revenues and milestones for HPN217 from the collaboration, which is expected to terminate on October 12.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HARP:
- Harpoon Therapeutics announces first patients with SCLC dosed in HPN328 trial
- Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort
- Harpoon Therapeutics trading resumes
- Harpoon Therapeutics trading halted, volatility trading pause
- Harpoon Therapeutics price target lowered to $40 from $80 at Canaccord